Sphingosine-1-phosphate and estrogen signaling in breast cancer

Advances in Biological Regulation

Volumn 60, Issue , 2016, Pages 160-165

  Maczis, Melissa ^a   Milstien, Sheldon ^a   Spiegel, Sarah ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Breast cancer; Estradiol; FTY720 Fingolimod; Sphingosine kinase; Sphingosine 1 phosphate

Indexed keywords

ESTROGEN; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANALOGS AND DERIVATIVES; ANIMAL; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84958755243     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2015.09.006     Document Type: Review

References (46)

1. Alvarez S.E., Harikumar K.B., Hait N.C., Allegood J., Strub G.M., Kim E.Y., et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010, 465:1084-1088.
2. Antoon J.W., Meacham W.D., Bratton M.R., Slaughter E.M., Rhodes L.V., Ashe H.B., et al. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J. Mol. Endocrinol. 2011, 46:205-216.
3. Antoon J.W., White M.D., Slaughter E.M., Driver J.L., Khalili H.S., Elliott S., et al. Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol. Ther. 2011, 11:678-689.
4. Bayraktar S., Gluck S. Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res. Treat. 2013, 138:21-35.
5. Carroll B., Donaldson J.C., Obeid L. Sphingolipids in the DNA damage response. Adv. Biol. Regul. 2015, 58:38-52.
6. Datta A., Loo S.Y., Huang B., Wong L., Tan S.S., Tan T.Z., et al. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget 2014, 5:5920-5933.
7. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
8. Deng J., Liu Y., Lee H., Herrmann A., Zhang W., Zhang C., et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 2012, 21:642-654.
9. Donoviel M.S., Hait N.C., Ramachandran S., Maceyka M., Takabe K., Milstien S., et al. Spinster 2, a sphingosine-1-phosphate transporter, plays a critical role in inflammatory and autoimmune diseases. FASEB J. 2015, (in press).
10. Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007, 148:3236-3245.
11. Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K., et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257.
12. Hait N.C., Avni D., Yamada A., Nagahashi M., Aoyagi T., Aoki H., et al. The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERalpha expression and enhances hormonal therapy for breast cancer. Oncogenesis 2015, 4:e156.
13. Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 2008, 9:139-150.
14. Hobson J.P., Rosenfeldt H.M., Barak L.S., Olivera A., Poulton S., Caron M.G., et al. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 2001, 291:1800-1803.
15. Lee H., Deng J., Kujawski M., Yang C., Liu Y., Herrmann A., et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med. 2010, 16:1421-1428.
16. Liang J., Nagahashi M., Kim E.Y., Harikumar K.B., Yamada A., Huang W.C., et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013, 23:107-120.
17. Liu K., Guo T.L., Hait N.C., Allegood J., Parikh H.I., Xu W., et al. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine Kinase-2 inhibitor and anticancer Agent. Plos One 2013, 8:e56471.
18. Liu Y., Deng J., Wang L., Lee H., Armstrong B., Scuto A., et al. S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood 2012, 120:1458-1465.
19. Maceyka M., Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 2014, 510:58-67.
20. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
21. Marino M., Galluzzo P., Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genomics 2006, 7:497-508.
22. Martin J.L., de Silva H.C., Lin M.Z., Scott C.D., Baxter R.C. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol. Cancer Ther. 2014, 13:316-328.
23. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644.
24. Nagahashi M., Hait N.C., Maceyka M., Avni D., Takabe K., Milstien S., et al. Sphingosine-1-phosphate in chronic intestinal inflammation and cancer. Adv. Biol. Regul. 2014, 54C:112-120.
25. Nagahashi M., Ramachandran S., Kim E.Y., Allegood J.C., Rashid O.M., Yamada A., et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res. 2012, 72:726-735.
26. Nava V.E., Hobson J.P., Murthy S., Milstien S., Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp. Cell Res. 2002, 281:115-127.
27. Newton J., Lima S., Maceyka M., Spiegel S. Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy. Exp. Cell Res. 2015, 333:195-200.
28. Nishi T., Kobayashi N., Hisano Y., Kawahara A., Yamaguchi A. Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim. Biophys. Acta 2014, 841:759-765.
29. Panneer Selvam S., De Palma R.M., Oaks J.J., Oleinik N., Peterson Y.K., Stahelin R.V., et al. Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. Sci. Signal. 2015, 8:ra58.
30. Pyne N.J., Ohotski J., Bittman R., Pyne S. The role of sphingosine 1-phosphate in inflammation and cancer. Adv. Biol. Regul. 2014, 54:121-129.
31. Pyne N.J., Tonelli F., Lim K.G., Long J.S., Edwards J., Pyne S. Sphingosine 1-phosphate signalling in cancer. Biochem. Soc. Trans. 2012, 40:94-100.
32. Romero Rosales K., Singh G., Wu K., Chen J., Janes M.R., Lilly M.B., et al. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. Biochem. J. 2011, 439:299-311.
33. Ruckhaberle E., Rody A., Engels K., Gaetje R., von Minckwitz G., Schiffmann S., et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat. 2008, 112:41-52.
34. Saha Roy S., Vadlamudi R.K. Role of estrogen receptor signaling in breast cancer metastasis. Int. J. Breast Cancer 2012, 2012:654698.
35. Shamseddine A.A., Airola M.V., Hannun Y.A. Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes. Adv. Biol. Regul. 2015, 57:24-41.
36. Strub G.M., Paillard M., Liang J., Gomez L., Allegood J.C., Hait N.C., et al. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J. 2011, 25:600-612.
37. Sukocheva O., Wadham C. Role of sphingolipids in oestrogen signalling in breast cancer cells: an update. J. Endocrinol. 2014, 220:R25-R35.
38. Sukocheva O., Wadham C., Holmes A., Albanese N., Verrier E., Feng F., et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J. Cell Biol. 2006, 173:301-310.
39. Sukocheva O., Wadham C., Xia P. Estrogen defines the dynamics and destination of transactivated EGF receptor in breast cancer cells: role of S1P(3) receptor and Cdc42. Exp. Cell Res. 2013, 319:455-465.
40. Sukocheva O., Wang L., Verrier E., Vadas M.A., Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology 2009, 150:4484-4492.
41. Takabe K., Kim R.H., Allegood J.C., Mitra P., Ramachandran S., Nagahashi M., et al. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J. Biol. Chem. 2010, 285:10477-10486.
42. Takabe K., Paugh S.W., Milstien S., Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev. 2008, 60:181-195.
43. Takabe K., Spiegel S. Export of sphingosine-1-phosphate and cancer progression. J. Lipid Res. 2014, 9:1839-1846.
44. Truman J.P., Garcia-Barros M., Obeid L.M., Hannun Y.A. Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim. Biophys. Acta 2014, 1841:1174-1188.
45. Watson C., Long J.S., Orange C., Tannahill C.L., Mallon E., McGlynn L.M., et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am. J. Pathol. 2010, 177:2205-2215.
46. Watson D.G., Tonelli F., Alossaimi M., Williamson L., Chan E., Gorshkova I., et al. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell Signal. 2013, 25:1011-1017.